 Sage Therapeutics Inc NASDAQ: SAGE said on Tuesday its candidate drug for depression that it developed in collaboration with Biogen Inc was found effective in alleviating the symptoms, as per the results of the late-stage trial. Despite meeting the goal of the study, Sages stock tanked about 17 this morning. 